Argenica Therapeutics LtdASX: AGN

First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Oct 17, 2022 at 2:54 AM UTC · Issued by Argenica Therapeutics Ltd

Argenica Therapeutics Ltd has released a press release.

View Attachment